Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | CPB1 | P15086 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | MGLL | Q99685 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1839628 | 0.85 | SMN1; SMN2 (0.76) | KMT2AALDH1A1SMN1; SMN2PKMLMNA | |
| SCHEMBL6210916 | 0.83 | ALDH1A1 (0.79) | KMT2AALDH1A1SMN1; SMN2PKMLMNA | |
| SCHEMBL1720183 | 0.82 | MGLL (0.82) | KMT2AALDH1A1CPB1MGLLMEN1 | |
| SCHEMBL27508890 | 0.80 | RAB9A (0.84) | KMT2AALDH1A1SMN1; SMN2PKMLMNA | |
| SCHEMBL7238822 | 0.79 | ALDH1A1 (0.64) | KMT2AALDH1A1SMN1; SMN2PKMLMNA | |
| SCHEMBL16026437 | 0.78 | ALDH1A1 (0.83) | KMT2AALDH1A1SMN1; SMN2PKMLMNA | |
| SCHEMBL12593269 | 0.78 | SMN1; SMN2 (0.68) | KMT2AALDH1A1SMN1; SMN2PKMLMNA | |
| SCHEMBL27080814 | 0.78 | SMN1; SMN2 (0.73) | KMT2AALDH1A1SMN1; SMN2PKMLMNA | |
| SCHEMBL6210873 | 0.77 | HSD11B1 (0.68) | KMT2AALDH1A1SMN1; SMN2PKMLMNA | |
| SCHEMBL2556107 | 0.77 | CPB1 (0.67) | KMT2AALDH1A1CPB1MGLLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | claimed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | claimed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | claimed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | KMT2A 1395/4885ALDH1A1 14/4885SMN1; SMN2 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.